STOK

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company based in Bedford, Massachusetts, focused on treating severe genetic diseases by upregulating protein expression with RNA-based medicines.

Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform, Stoke develops antisense oligonucleotides (ASOs) designed to increase protein production from a patient’s remaining healthy copy of a gene, with the goal of restoring protein levels close to normal and modifying the course of disease.

The company, founded in 2014, is building a pipeline that includes zorevunersen, a first-in-class, potentially disease-modifying therapy in development for Dravet syndrome and other severe genetic epilepsies.